Among these matched pairs, 1829 unrelated bone marrow transplants (UR-BMT) were performed. The initial 500 UR-BMT transplanted from January 1993 to October 1995 were analyzed as of July 1998. Engraftment was achieved in 95% of cases. Probability of the occurrence of grade III and IV acute GVHD was 18.4%. The rate of disease-free survival (DFS) of the patients who had standard-risk leukemia and did not suffer from grade III or IV acute GVHD (n = 154) was 60-71% and the rate of survival of patients with aplastic anemia was 56%. It can be stated that UR-BMT is a modality of treatment which is as effective as related BMT if the occurrence of grade III or IV acute GVHD is predicted and prevented.
Allogeneic bone marrow transplantation (BMT) from HLAidentical sibling donors has been accepted as a cureoriented treatment for patients with hematological malignancies, [1] [2] [3] syndromes of marrow failure [4] [5] [6] and certain hereditary disorders. 7 It has been, nevertheless, a possible modality of treatment only for approximately one-third of the patients for whom BMT is the first choice of treatment because of the lack of HLA-matched related donors. To provide the remaining patients with the chance of BMT, several investigators have explored the use of other sources of marrow, including partially HLA-mismatched family members 8, 9 and unrelated donors who are phenotypically closely matched for HLA-A,B and DR antigens. The first transplants involving unrelated donors were reported in the mid-1970s, [10] [11] [12] [13] [14] followed by several other reports; [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] then a large-scale study based on a publically established bone marrow donor bank was reported. 30, 31 Since the mid-1980s, Japanese hematologists as well as patients and their families also started organizing a bone marrow donor bank. After successful experience with local marrow donor banks, 32, 33 the Japan Marrow Donor Program (JMDP) was finally created at the end of 1991. In this report, we present the results of the initial 500 marrow transplants performed from unrelated donors identified through JMDP between January 1993 and October 1995, and evaluated as of July 1998.
Materials and methods

JMDP
The JMDP was established in December 1991 with the cooperation of the Japanese Red Cross and Japan Marrow Donor Foundation under the auspices of the Japanese Ministry of Health and Welfare. Its principles and policies are basically similar to those of the marrow donor registries in the United States and European countries. 17, 34, 35 JMDP involves 68 local blood centers for the HLA class I and II serological typing of volunteer donors and involves the central blood center for the accumulation of this HLA information for matching to registered patients and for HLA DNA typing among HLA serologically-matched pairs. JMDP has also approved 129 units in 101 institutes experienced in allogeneic BMT as transplant and harvest centers distributed throughout the country. 36 
Donor recruitment and selection
The recruitment of volunteer marrow donors was initiated in January 1992, and by December 1998 the number of persons enquiring about marrow donation reached approximately 260 000; among them 122 365 persons were registered after confirmation of their willingness to donate followed by HLA-A,B serological typing. HLA-DR serological typing had been also performed for 83.3% of these registered donors by December 1998. The matching of donors and recipients was based on HLA-serotyping according to the standard technique, 37 and JMDP has approved 6/6 matched donors as suitable for the corresponding patients. Characteristics of the initial 500 donors are shown in Table 1 .
Patients
From June 1992 to December 1998, 7207 patients were registered in the JMDP following the evaluation of unrelated BMT indications according to the recipient criteria of JMDP by the Central Coordination Committee. The study population is the initial 500 patients with malignant or nonmalignant disease who received marrow transplants at 103 of 129 transplant centers approved by JMDP (appendix). Patient characteristics are also summarized in Table 1 . Among the leukemia patients, those with acute leukemia in first remission and those with chronic myelogenous leukemia in primary chronic phase at the time of BMT were designated as the standard-risk group and those in the other situations were designated as the high-risk group. Patients received a variety of preparative regimens, which are summarized in Table 2 . Methods of graft-versus-host disease (GVHD) prophylaxis also varied, and are also listed in Table 2 .
Data collection and statistical analysis
Among the 103 institutes where the 500 bone marrow transplants were performed, 15 (15%) undertook more than 10 procedures, 23 (22%) institutes performed five to nine procedures, and the remaining 65 (63%) between one and four procedures. The median length of follow-up was 3 years and 7 months (range, 3 years and 2 months to 5 years and 5 months). The day of engraftment was defined as the first of 3 consecutive days on which the neutrophil count exceeded 500/mm 3 . Thus, patients in whom engraftment did not occur were designated graft rejection. Patients with initial engraftment in whom a severely hypocellular marrow and/or an absolute neutrophil count of less than 500/mm 3 recurred were considered to have secondary graft failure. The diagnosis and the staging of acute and chronic GVHD were measured according to the standard criteria. 38, 39 The probability of disease-free survival, GVHD and relapse were calculated by Kaplan-Meier analysis. 40 
Results
Identification of unrelated donors
By October 1995, 3509 registered patients were referred to 68 222 HLA-A, B, DR typed donor candidates. Then 8789 donor candidates (13% of the registered donor candidates) 
GVHD prophylaxis
GVHD
In 490 of 500 evaluable cases who survived more than 7 days after transplantation, the probability of having grade II, III or IV acute GVHD was 40.1%, and that of grade III or IV 18.4% ( Figure 1 ). The respective occurrence of grade II, III, IV and grade III, IV acute GVHD for each decade of patient age was as follows: 0-9 years old (n = 18 .4%. The probability of having either limited or extensive chronic GVHD among 343 patients who survived more than 100 days after transplantation was 44% ( Figure  2 ), among which the probability of having limited-type disease was 21.7% and the probability of extensive-type 28.6%. 
Survival of patients with leukemia
The probability of disease-free survival (DFS) among patients with acute lymphocytic leukemia transplanted in first complete remission (1st CR), 2nd CR, 3rd or subsequent CR and non-CR was 56%, 33%, 22% and 12%, respectively ( Figure 3 ). The probability of DFS among patients with acute myelogenous leukemia transplanted in 1st CR, 2nd CR, 3rd or subsequent CR and non-CR was 71%, 55%, 43% and 12%, respectively ( Figure 4 ). DFS for chronic myelogenous leukemia transplanted in first chronic phase (CP), second CP, accelerated phase and blastic phase was 45%, 36%, 41% and 10%, respectively ( Figure 5) . DFS of 182 patients with standard-risk leukemia was then analyzed according to the severity of acute GVHD. DFS of patients who had grade 0-II acute GVHD was 60-71%, whereas that of patients with grade III or IV acute GVHD was 6-17% ( Figure 6 ), reflecting a statistically significant difference (P Ͻ 0.0001).
Patients with myelodysplastic syndrome
The probability of DFS among 33 patients with myelodysplastic syndrome varied from 50% to 10%, according to the disease category and this is shown in Figure 7 . Probability of disease-free survival among patients with myelodysplastic syndrome; patients with chronic myelomonocytic leukemia (n = 4) (a) with refractory anemia (n = 9) (b) refractory anemia with excess blast (RAEB), (n = 7) (c) and with RAEB in transformation (n = 13) (d).
Patients with aplastic anemia
Among 48 patients with aplastic anemia, the probability of overall survival was 56%. Survival of patients under 15 years of age was 81% and that of patients aged 16 or over was 32% (Figure 8 ).
Patients with hereditary disorders
Probability of survival among 17 patients with hereditary disorders was 66%. These cases included a single case of adrenoleukodystrophy, Chediak-Higashi syndrome, Hurler's disease, I-cell disease, metachromatic leukodystrophy, and pure red cell aplasia; two cases each of severe combined immunodeficiency syndrome and Wiskott-Aldrich syndrome, three cases of metachromatic leukodystrophy, and four cases of familial hemophagocytic lymphohistiocytosis ( Figure 9 ).
Complications and causes of death
Among the 500 study patients, 278 of 497 reported cases (56.0%) died, and the primary and secondary causes of their death are listed in Table 3 . Forty-nine (17.6%) died within 1 month after transplantation because of sepsis (18%), hemorrhage (15%), renal failure (11%) or other reasons. Two hundred and twenty-nine patients (82.3%) died more than 1 month after transplantation because of GVHD (19%), relapse of leukemia (18%), interstitial pneumonitis (14%) or other reasons.
Performance status of surviving patients
The latest performance status (Karnofsky score) was evaluated. One-hundred and forty-two of 213 surviving cases (86%) had a performance score of 90 or 100, 12 (6%) had a score of 80, 25 (8%) had a score between 20 and 70 (Table 4) .
Discussion
The JMDP's experience since its establishment has indicated that some people are, indeed, willing to donate their bone marrow in Japan, and that there is good cooperation in this regard between medical and non-medical fields, and good work is being done at many medical institutions. 32, 33, 36 The results of allogeneic bone marrow transplantation from HLA genotypically identical siblings, which started in 1974 in Japan, revealed that approximately 65% of patients with leukemia at standard risk and 40% of patients at high risk could have prolonged leukemia-free survival. 3, 41 It was also revealed that the survival rate among patients with aplastic anemia is approximately 80%, 6 around 50% among patients with myelodysplastic syndrome 3 and about 40% 42 among patients with hereditary disorders, when patients received HLA genotypically identical grafts. These results, which are equivalent or slightly superior to those of previous reports, 1,2,4,7,43 might be due to the genetic homogeneity of Japanese people. 41 On the other hand, some experiences of marrow transplantation with related donors other than HLA genotypically identical siblings among Japanese 9 resulted in a relatively low survival rate except in cases receiving a marrow graft from a HLA-phenotypically identical family member. For this reason, the JMDP has provided only a donor whose HLA-A, B, and DR antigens were serologically 6/6 matched to the corresponding patient until the technologies assuring the success of UR-BMT are established. Although the JMDP did not restrict the diversity of the results of HLA-class II DNA typing for the final selection of donors, many transplant centers did not use donor candidates whose DRB1 DNA typing was mismatched to the patients. The probability of graft failure, which was evaluated by calculating the probability of both initial myeloid engraftment and secondary marrow failure, was 5%. This was higher than the rate observed with HLA-matched sibling transplants 3, 6, 41 and equivalent to the previous report of UR-BMT, 30 and this is associated with the background disease (higher rate with aplastic anemia and hereditary disease than with hematological malignancies). The probability of having acute GVHD was higher in these study patients than in recipients of marrow from HLA-matched siblings; the probability of having grade II, III or IV acute GVHD was 40.1% and grade III or IV was 18.4%. These are significantly higher than the probabilities observed in HLA-matched sibling transplants among Japanese (grade II, III, IV GVHD: 15%; III, IV GVHD: 5% 41 ), although they are still lower than in the previous report by Kernan et al 30 (grade II, III, IV: 64%; grade III, IV: 47%) and the reports by others 17, 18 in which most of the recipients and donors were Caucasians. Chronic GVHD was observed in 136 of 343 evaluable cases (44%) who survived more than 100 days. It was not significantly higher than among Japanese patients who received the marrow from HLA identical siblings 3 or that reported by the NMDP. 30 Among 225 patients with acute leukemia, the probability of disease-free survival was 56-71% for standard-risk patients and 12-55% for high-risk patients, virtually the same results as obtained from HLA-matched sibling BMT among Japanese. 3, 41 In acute leukemia, these equivalent results as to the probability of disease-free survival of UR-BMT with respect to related BMT, despite the frequent occurrence of severe acute GVHD, might come from the low frequency of leukemia relapse after the UR-BMT over that after related BMT (unpublished observation). Further study is required to confirm the low frequency of leukemia relapse with UR-BMT. Nevertheless, this important issue may shed light on the mechanism of the so-called 'GVL effect'.
On the other hand, among 179 patients with CML, the probability of DFS was 45% for patients at standard risk, which was basically equivalent to that of patients at high risk transplanted from HLA-identical siblings among Japanese. This non-optimistic result seen in CML, especially in the standard risk group, might be partially explained by the fact that most patients had to wait for an unrelated marrow graft for more than 2 years from initial diagnosis and also by the fact that they suffered from relatively severe acute GVHD more frequently than the average (data not shown).
When the probability of disease-free survival for those patients with standard-risk leukemia (n = 182) was analyzed according to the severity of acute GVHD (with or without grade III or IV acute GVHD), the patient group without severe acute GVHD showed a 60-71% probability of DFS. This was equivalent to that of related BMT, 41 suggesting that UR-BMT could be as effective as related BMT if severe acute GVHD is prevented. Grade III or IV acute GVHD was particularly life-threatening among the patients in this study, whereas the survival rate of patients with less than grade II GVHD was equivalent to that of the patients who received an HLA-matched sibling transplant. Therefore, development of methods to predict severity of acute GVHD and to control it is of primary importance for UR-BMT even among Japanese.
Among 36 patients with aplastic anemia, the probability of overall survival was 56%, 81% for those under age 15 years of age and 32% for those Ͼ16 years of age. This is not surprising when one considers that most patients already had a long history of transfusion by the time of transplantation. These results, which are superior to those of the previous report, 30 might be due to the low rejection rate among our cases.
Survival among 17 patients with hereditary disorders was 66%, and among myelodysplastic syndrome 36%, also suggesting that UR-BMT is an effective treatment for these disease categories. The causes of death among 278 patients were analyzed, and an increased risk of death was independently associated with advanced disease at the time of BMT and higher than grade III acute GVHD. Since the JMDP primarily accepted patients with a standard disease risk for initiation of the donor search, advance of the disease is considered to be due to the length of wait for an appropriate donor. This situation is now being remedied by the expansion of the donor pool and a faster coordination system.
Despite the increased risk of graft failure and severe acute GVHD, this study demonstrates that in a large patient population transplantation of marrow from unrelated donors can be an effective treatment for certain hematologic malignancies, as well as marrow failure syndrome and certain hereditary disorders. Prophylactic and therapeutic maneuvers for GVHD, as well as more optimal approaches to the selection of unrelated donor 44 are developing rapidly. Therefore, it is reasonable to expect further improvement in the results of UR-BMT in the near future. Safety of marrow donation was also shown through this experience and will be reported soon. Nevertheless, the economic, physical, psychological and time-related burdens of volunteer donors are still problems. To resolve them, the further development of the marrow donor bank system as well as improvement in hematopoietic stem cell collection techniques will be essential.
